Who Will Be The First To Get A Psychedelic Drug Through The FDA To Commercialization?Psyched Wellness Is Laser Focused On Bringing Truly Differentiated Mushroom Products To MarketAtai Life Sciences: The Next Unicorn Of The Psychedelics SectorATAI Life Sciences Announces Closing of $125 Million Series C Financing RoundRritual Mushrooms Is Pioneering The Future Of Functional FoodsMindMed’s Drug Delivery Business Is One That Psychedelic Sector Investors Need To Be WatchingPure Extracts Technologies Corporate UpdateNova Mentis Life Science Announces Receipt of Pilz Shareholder ApprovalField Trip Health Ltd. Announces Expansion to The Netherlands and Launch of Proprietary Truffle ProgramPsyched Wellness Ltd. Announces Insider Buying and Option Grant to Professor NuttMindMed Receives Approval of Protocol Design to Evaluate Microdoses of LSD For Adult ADHD In Phase 2a Clinical Trial froTryp Appoints Dr. Jim Gilligan, PhD, MBIS, as President and Chief Scientific OfficerHavn Life Announces Launch of a Range of Natural Health ProductsCybin Corp. Will Make Its Debut Today On The NEO Under The Symbol “CYBN”Tryp Therapeutics Has “The Right Stuff” To Bring Psychedelic Therapies Through To CommercializationMindset Pharma Closes Ontario Brain Institute Funding and Announces Private Placement OfferingNuminus Wellness Is Executing Flawlessly On Their B2B Strategy via Numinus BiosciencesEntheon Biomedical Corp. (formerly MPV Exploration Inc.) Announces Completion of Amalgamation and Final Approval from thCybin Completes Reverse Take-Over TransactionThe Psychedelic Sector Is Getting A Major Momentum Boost Post U.S. Election
Back

Wake Network Is Laser Focused On Advancing Fungi-Based Medicine Through Cutting Edge Technology and Clinical Research

Oct 16, 2020 • 8:12 AM EDT
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

A few months ago, we highlighted Wake Network as a psychedelic therapy company that we consider to be a leading play on an emerging industry and want to provide an update on the opportunity.

Wake Network is laser focused on advancing fungi and plant-based medicine by leveraging clinical research, wellness professionals, and technology. The company has developed a regenerative feedback loop that allows it to research, monitor and incorporate results from clinical studies to personalize medicine to reduce the level of ambiguous results from traditional medicine.

A Differentiated Growth Story

The psychedelic therapy company has been able to differentiate itself from competitors by executing on a Jamaica based joint venture and by attracting strategic human capital to the leadership team.

Wake Jamaica is a separate division of the business and is a cultivation-focused joint venture subsidiary that is managed by Pauline Smith and her group of mycologists and farmers. Earlier this year, Wake opened a facility offers psilocybin-based therapy on a 3,000-acre mountain retreat, private beach and pavilion in Jamaica. At the facility, licensed professionals assess patients and track biofeedback.

In the psychedelic therapy industry, human capital is one of the most important aspects of any company. When we are analyzing a psychedelic therapy business, we spend time analyzing the leadership team and are most favorable on the businesses that are led by executives that have previously worked in the pharmaceutical industry and that have experience with the Food and Drug Administration (FDA) clinical trial process.

In regards to the leadership team, we are excited about the value that Dr. Olga Chernoloz adds to the business as the Director of Psychedelic Research.. Dr. Chernoloz is a specialist in the pharmacology of psychoactive compounds and is a trained neuropharmacologist and a registered pharmacist.

Dr. Chernoloz provides scientific advisory to companies in cannabinoid and psychedelic space. She is a scientific advisor to The Toronto Centre for Psychedelic Science and is interested in the therapeutic potential of cannabinoids and psychedelic drugs in the treatment of mental health disorders. We are favorable on Dr. Chernoloz’s background and expect her to play an important role in the advancement of the business.

We believe that Wake Network represents an attractive play on the psychedelic therapy market and has significant potential catalysts for growth. The company is privately held, and we expect it to complete a go-public transaction in the near future. If you are interested in learning Wake Network, please send an email to support@technical420.com with the subject “Wake Network” to be added to our distribution list.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link